Singhal Priya 4

What Happened

• Priya Singhal, Head of Development at Biogen (BIIB), exercised/converted 1,829 derivative shares on 2026-01-30 (exercise price reported as $0.00). To cover tax withholding, 582 shares were surrendered/withheld at $179.89 per share (value ≈ $104,696). Separately, 748 shares were sold in an open-market transaction on 2026-02-02 at $179.30 per share (proceeds ≈ $134,116). The filing records both the conversion/exercise and the subsequent dispositions (tax withholding + market sale).

Key Details

• Transaction dates and prices:
  • 2026-01-30: Exercise/conversion of 1,829 derivative shares at $0.00.
  • 2026-01-30: 582 shares surrendered/withheld for tax liability at $179.89 (≈ $104,696).
  • 2026-02-02: 748 shares sold in the open market at $179.30 (≈ $134,116).
• Shares owned after the transactions: Not specified in the provided filing data.
• Footnote: The award was granted to the reporting person on February 1, 2023 and vests in three equal installments on each anniversary of the grant date.
• Transaction codes: M = exercise/conversion of derivative; F = tax withholding; S = open-market sale.
• Filing date: Report filed 2026-02-03. (No indication in the filing provided that this was late.)

Context

• This was an exercise/conversion of derivative awards with shares withheld to cover taxes and a separate open-market sale — a common cashless-style outcome where an insider converts vested awards and disposes of some shares to meet tax obligations or take proceeds.
• These transactions are routine insider actions to satisfy taxes or diversify; they are factual disclosures and do not, by themselves, indicate management’s view of the company’s prospects.